Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Payables (2016 - 2025)

UroGen Pharma's Payables history spans 10 years, with the latest figure at $12.1 million for Q4 2025.

  • For Q4 2025, Payables fell 55.75% year-over-year to $12.1 million; the TTM value through Dec 2025 reached $12.1 million, down 55.75%, while the annual FY2025 figure was $12.1 million, 55.75% down from the prior year.
  • Payables reached $12.1 million in Q4 2025 per URGN's latest filing, up from $10.3 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $27.4 million in Q4 2024 to a low of $2.5 million in Q2 2022.
  • Average Payables over 5 years is $10.2 million, with a median of $9.6 million recorded in 2022.
  • Peak YoY movement for Payables: plummeted 56.81% in 2023, then skyrocketed 409.85% in 2024.
  • A 5-year view of Payables shows it stood at $12.1 million in 2021, then tumbled by 54.33% to $5.5 million in 2022, then skyrocketed by 199.22% to $16.5 million in 2023, then soared by 65.87% to $27.4 million in 2024, then tumbled by 55.75% to $12.1 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Payables are $12.1 million (Q4 2025), $10.3 million (Q3 2025), and $13.6 million (Q2 2025).